AI & Automation Solutions

Cloverleaf Bio, an RNA therapeutics company developing engineered transfer RNA-based cancer treatments, has closed a $33 million seed financing round. The oversubscribed round was led by 4BIO Capital, with participation from AbbVie Ventures, Eli Lilly and Company, Boehringer Ingelheim Venture Fund, Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge. The New Haven-based company will use the funds to advance two lead programmes: an inhibitory tRNA asset targeting hepatocellular carcinoma through early clinical testing and an antibody-tRNA conjugate asset for colorectal cancer through preclinical development. Cloverleaf's platform targets RNA-modifying enzymes that cancer cells depend on during proliferation. In preclinical studies, the lead compound CLB-001 demonstrated greater potency and selectivity for cancerous cells whilst showing no signs of systemic toxicity. The company is a Yale University spinout, founded by Austin Draycott, Cole Lewis, and Wendy Gilbert.

Novartis (NVS) stock falls 3% after heart drug fails late-stage trial. Novartis (NVS) stock fell over 3% Monday after pelacarsen failed to reduce cardiovascular events in the 8,000-patient Lp(a)HORIZON trial. Year-to-date gains now sit at 14%. By Trader Edge September 7, 2026 3 Mins Read Tldr. * Novartis stock fell over 3% Monday after its experimental drug pelacarsen failed a late-stage cardiovascular trial * The Lp(a)HORIZON trial involved more than 8,000 patients and missed its primary goal of reducing heart attacks, strokes and cardiovascular deaths * Pelacarsen did lower lipoprotein(a) blood levels, but this did not translate into fewer cardiovascular events * The failure raises questions about rival Lp(a)-targeting drugs from Amgen and Eli Lilly, which use a different pathway * Novartis year-to-date gains now sit at 14%, down from higher levels before Monday's drop Novartis stock fell more than 3% in European trading Monday after the company revealed its experimental heart drug pelacarsen failed to meet its primary goal in a major late-stage clinical trial. The drop cut the stock's year-to-date gain to around 14%. The trial in question is the Lp(a)HORIZON study, which enrolled more than 8,000 patients with elevated levels of lipoprotein(a), a cholesterol-carrying particle in the blood that is linked to heart disease. Pelacarsen did succeed in lowering Lp(a) levels. But lower blood levels did not translate into fewer cardiovascular events, like heart attacks, strokes, or death. That gap between a biomarker moving and actual patient outcomes is a tough result for any drug to recover from. Chief Medical Officer Shreeram Aradhye acknowledged the disappointment, saying the results were "not what we hoped for," but added the data still advances understanding of the relationship between Lp(a) lowering and cardiovascular risk. Questions for rival drugs too. The failure does not only affect Novartis. Amgen and Eli Lilly are both developing their own drugs that target Lp(a), though through a different biological pathway. The pelacarsen outcome raises questions about whether lowering Lp(a) alone is enough to protect the heart. No drug specifically targeting lipoprotein(a) has been approved yet, despite elevated Lp(a) affecting roughly one in five people worldwide. Pelacarsen was licensed by Novartis from Ionis Pharmaceuticals. It is an antisense oligonucleotide, meaning it targets the production of Lp(a) at its source. More pressure on the pipeline. Analysts at Jefferies noted that the broader success of existing cardiovascular therapies, combined with the rise of GLP-1 obesity drugs, is raising the bar for new heart treatments to prove their value in outcome trials. The trial failure also comes less than a week after Novartis paused eight trials of a separate experimental cell therapy for autoimmune and neurological disorders following the deaths of three patients. Jefferies said recent positive data from a multiple sclerosis trial should help soften the blow for investors. But the bank also noted that Novartis now faces pressure to deliver positive results from a drug it acquired through its $12 billion Avidity Biosciences deal to justify that price tag. Full results from the Lp(a)HORIZON trial are expected to be presented at a future medical congress. Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions - all in one powerful platform. Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount. Limited Time Offer Get 3 free stock ebooks. Discover top-performing stocks in AI, Crypto, and Technology with expert analysis. * Top 10 AI Stocks - Leading AI companies * Top 10 Crypto Stocks - Blockchain leaders * Top 10 Tech Stocks - Tech giants Futures & Crypto Trader | Sharing charts, strategies, & mindset tips to help you level up | Not Financial Advice Follow on X @Pro_Trader_Edge September 7, 2026

Promising healthcare stocks to watch now - september 6th. Eli Lilly and Company, Moderna, and UnitedHealth Group are the three Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of companies involved in the healthcare industry, including pharmaceuticals, biotechnology, medical devices, healthcare services, and health insurance. For investors, these stocks may offer growth opportunities driven by medical innovation and demographic trends, but they can also face risks from regulation, clinical-trial results, pricing pressures, and changing healthcare policies. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days. Stocks & Bonds Eli Lilly and Company (LLY). Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Discover more Moderna (MRNA). Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. UnitedHealth Group (UNH). UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.